During their development within the vertebrate host, parasites infect hepatocytes and red blood cells. Within these cells, parasites are surrounded by a parasitophorous vacuole membrane (PVM). The PVM plays an essential role for the interaction of parasites with their host cells; however, only a limited number of proteins of this membrane have been identified so far. This is partially because systematic proteomic analysis of the protein content of the PVM has been difficult in the past, due to difficulties encountered in attempts to separate the PVM from other membranes such as the parasite plasma membrane. In this study, we adapted the BioID technique to -cultivated blood stage parasites and utilized the promiscuous biotin ligase BirA* fused to PVM-resident exported protein 1 to biotinylate proteins of the PVM. These we further processed by affinity purification, liquid chromatography-tandem mass spectrometry (LC-MS/MS), and label-free quantitation, leading to a list of 61 known and candidate PVM proteins. Seven proteins were analyzed further during blood and liver stage development. This resulted in the identification of three novel PVM proteins, which were the serine/threonine protein phosphatase UIS2 (PlasmoDB accession no. PBANKA_1328000) and two conserved proteins with unknown functions (PBANKA_0519300 and PBANKA_0509000). In conclusion, our report expands the number of known PVM proteins and experimentally validates BioID as a powerful method to screen for novel constituents of specific cellular compartments in . Intracellular pathogens are often surrounded by a host-cell derived membrane. This membrane is modified by the pathogens to their own needs and is crucial for their intracellular lifestyle. In parasites, this membrane is referred to as the PVM and only a limited number of its proteins are known so far. Here, we applied in rodent parasites a method called BioID, which is based on biotinylation of proximal and interacting proteins by the promiscuous biotin ligase BirA*, and demonstrated its usefulness in identification of novel PVM proteins.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784244 | PMC |
| http://dx.doi.org/10.1128/mSphere.00522-17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interleukin 8 exacerbates age-related hearing loss through regulating perivascular-resident macrophage-like melanocytes viability and the permeability of the endothelial cells.
Int Immunopharmacol
January 2025
Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361005, China; Xiamen Key Laboratory of Otolaryngology Head and Neck Surgery, Xiamen, Fujian 361005, China. Electronic address:
The etiology and mechanism causing Age-related hearing loss (ARHL) are not understood. This study aimed to investigate the molecular mechanism of interleukin 8 (IL-8) associated with ARHL. Sera content of IL-8 was significantly higher in patients with ARHL than normal volunteers and had a positive association with disease severity of ARHL.
View Article and Find Full Text PDFPlasmodium berghei liver stage parasites exploit host GABARAP proteins for TFEB activation.
Commun Biol
November 2024
Institute of Cell Biology, University of Bern, Bern, Switzerland.
Article Synopsis
- Plasmodium, the parasite that causes malaria, first infects liver cells (hepatocytes) before causing symptoms during the blood stage of infection, residing in a specialized compartment called the parasitophorous vacuole (PV).
- The study focuses on how the host's autophagy processes and a specific transcription factor, TFEB, play crucial roles in the development of Plasmodium's liver stages.
- Researchers discovered that certain ATG8 family proteins, particularly GABARAP, help recruit a complex (FLCN-FNIP) that inhibits TFEB, and that blocking this complex activates TFEB, revealing new details about the interaction between the parasite and host cell signaling during the liver infection phase
Inhaled GM-CSF administered during ongoing pneumovirus infection alters myeloid and CD8 T cell immunity without affecting disease outcome.
Front Immunol
October 2024
Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, Ghent, Belgium.
Granulocyte-macrophage colony stimulating factor (GM-CSF) is a pleiotropic cytokine, able to promote both myelopoiesis and activation of immune cells. Particularly in the lung, GM-CSF plays an important homeostatic role in the development and maintenance of alveolar macrophages, and is therefore considered to play a role in respiratory virus infections such as influenza and SARS-CoV-2, although the benefits of GM-CSF treatment in clinical studies remain inconclusive. To address this, we tested inhaled GM-CSF treatment in the Pneumonia Virus of Mice (PVM) mouse model.
View Article and Find Full Text PDFDistribution and species composition of potato viruses in the Novosibirsk region.
Vavilovskii Zhurnal Genet Selektsii
September 2024
Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
Among the many diseases that affect potato plants, viral infections are the most common and cause significant damage to farms, affecting both the yield and quality of potatoes. In this regard, an important condition for preserving the potato seed fund in Russia is systematic monitoring and early highly specific detection of potato viral infections. The purpose of the work is to study samples of potato varieties collected in the Novosibirsk region for the presence of viral infections using RT-PCR.
View Article and Find Full Text PDFVutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
N Engl J Med
January 2025
From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (M.F., J.D.G.), and Richmond Pharmacology (J.T.), London, and the Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow (M.C.P.) - all in the United Kingdom; Boston University School of Medicine (J.L.B.) and the Cardiovascular Division, Brigham and Women's Hospital (S.D.S.) - both in Boston; the Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA (R.M.W.); the Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN (M.G.); the Division of Cardiology, Penn Presbyterian Medical Center, University of Pennsylvania Health System, Philadelphia (B.D.); the Cardiology Department and French National Reference Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute and Clinical Investigation Centre 1430 at Hôpitaux Universitaires Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), and Institut Mondor de Recherche Biomédicale, INSERM, Université Paris Est Creteil, Creteil (T.D.), and the Department of Cardiology, French National Reference Center for Cardiac Amyloidosis, Bichat University Hospital, AP-HP, Paris (V.A.) - all in France; the Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Health Research Institute of the Puerta de Hierro Majadahonda-Segovia, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBER-CV), and Centro Nacional de Investigaciones Cardiovasculares (P.G.-P.), and CIBER-CV (J.G.-C.), Madrid, and the Department of Cardiology, Hospital Universitari de Bellvitge, Instituto de Investigación Biomédica de Bellvitge, and Universitat de Barcelona, Barcelona (J.G.-C.) - all in Spain; MedStar Heart and Vascular Institute, MedStar Health, and Georgetown University School of Medicine - both in Washington, DC (F.H.S.); the Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume (N.T.), and the Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto (K.T.) - both in Japan; the Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University Hospital Würzburg, and the Department of Medicine I, University Hospital Würzburg, Würzburg (C.M.), and the Division of Cardiovascular Imaging, University Hospital Münster, Münster (A.Y.) - both in Germany; the Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary (Z.P.); the Department of Cardiology, University Health Network of Toronto, Toronto (D.D.); University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.V.M.); the Victor Chang Cardiac Research Institute, the Cardiology Department, St. Vincent's Hospital, and the School of Clinical Medicine, University of New South Wales - all in Sydney (A.J.); the Department of Cardiology, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Université Libre de Bruxelles, Brussels (A.B.); the Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (D.K.); the Cardiology Department, Hospital Senhora da Oliveira-Guimarães, Guimarães, and the School of Medicine, University of Minho, Braga - both in Portugal (O.A.); the Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark (S.H.P.); the Division of Translational Cardiology and Clinical Registries, Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland (E.A.J.); Alnylam Pharmaceuticals, Cambridge, MA (A.S., P.P.G., K.L.B., E.Y., N.S., L.Y., J.C., S.A.E., J.V.); and Columbia University Irving Medical Center, New York (M.S.M.).
Article Synopsis
- Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a serious, progressive disease, and vutrisiran is a new treatment that works by reducing the production of transthyretin in the liver.
- In a double-blind trial involving 655 patients, those receiving vutrisiran had a lower risk of death and cardiovascular events compared to those on placebo, demonstrating significant efficacy.
- Vutrisiran also improved patient outcomes, showing less decline in walking distance and quality of life measurements over the study period compared to placebo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!